$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2023 Q2 Form 10-Q Financial Statement

#000141057823001157 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.655M $2.227M
YoY Change 7.14% -22.11%
% of Gross Profit
Research & Development $2.794M $2.924M
YoY Change -45.35% 11.77%
% of Gross Profit
Depreciation & Amortization $67.00K $67.00K
YoY Change -5.63% -9.46%
% of Gross Profit
Operating Expenses $2.794M $2.924M
YoY Change -45.35% 11.77%
Operating Profit -$5.449M -$5.151M
YoY Change -28.22% -5.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $120.0K $92.00K
YoY Change -78.18% -20.0%
Pretax Income -$5.329M -$5.059M
YoY Change -24.31% -5.62%
Income Tax
% Of Pretax Income
Net Earnings -$5.329M -$5.059M
YoY Change -24.31% -5.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.13 -$0.14
Diluted Earnings Per Share -$0.13 -$0.14
COMMON SHARES
Basic Shares Outstanding 39.41M 36.68M
Diluted Shares Outstanding 39.70M 36.74M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $748.0K $2.227M
YoY Change -93.89% -87.89%
Cash & Equivalents $546.0K $2.021M
Short-Term Investments $202.0K $206.0K
Other Short-Term Assets $372.0K $658.0K
YoY Change -16.4% -17.96%
Inventory
Prepaid Expenses
Receivables $93.00K $44.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.213M $2.929M
YoY Change -90.53% -84.79%
LONG-TERM ASSETS
Property, Plant & Equipment $799.0K $866.0K
YoY Change -25.47% -22.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.534M $4.943M
YoY Change -26.34% -24.31%
Total Long-Term Assets $4.534M $4.943M
YoY Change -26.34% -24.31%
TOTAL ASSETS
Total Short-Term Assets $1.213M $2.929M
Total Long-Term Assets $4.534M $4.943M
Total Assets $5.747M $7.872M
YoY Change -69.69% -69.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.190M $7.802M
YoY Change -1.93% 70.72%
Accrued Expenses $90.00K $171.0K
YoY Change 104.55% 140.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.691M $10.42M
YoY Change -1.98% 41.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.938M $2.290M
YoY Change -40.63% -41.76%
Total Long-Term Liabilities $1.938M $2.290M
YoY Change -40.63% -41.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.691M $10.42M
Total Long-Term Liabilities $1.938M $2.290M
Total Liabilities $9.629M $12.71M
YoY Change -13.33% 12.46%
SHAREHOLDERS EQUITY
Retained Earnings -$208.0M -$202.9M
YoY Change 11.83% 13.34%
Common Stock $204.4M $198.2M
YoY Change 5.43% 2.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.882M -$4.840M
YoY Change
Total Liabilities & Shareholders Equity $5.747M $7.872M
YoY Change -69.69% -69.48%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.329M -$5.059M
YoY Change -24.31% -5.62%
Depreciation, Depletion And Amortization $67.00K $67.00K
YoY Change -5.63% -9.46%
Cash From Operating Activities -$6.778M -$3.986M
YoY Change 10.5% 8.08%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $4.000K $2.005M
YoY Change -42.86% -25162.5%
Cash From Investing Activities $4.000K $2.005M
YoY Change -133.33% -11894.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.299M 3.230M
YoY Change
NET CHANGE
Cash From Operating Activities -6.778M -3.986M
Cash From Investing Activities 4.000K 2.005M
Cash From Financing Activities 5.299M 3.230M
Net Change In Cash -1.475M 1.249M
YoY Change -76.0% -133.71%
FREE CASH FLOW
Cash From Operating Activities -$6.778M -$3.986M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$6.778M -$3.986M
YoY Change 10.16% 7.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38475251
CY2023Q1 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36694078
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36641
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q1 dei City Area Code
CityAreaCode
201
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
488-0460
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
BCLI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39408554
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2021000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
206000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2211000
CY2023Q1 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
44000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
91000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
658000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2929000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3106000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4054000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
866000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4943000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2023Q1 us-gaap Assets
Assets
7872000
CY2022Q4 us-gaap Assets
Assets
8451000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7802000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6224000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
171000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
84000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1389000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1427000
CY2023Q1 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1060000
CY2022Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1065000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10422000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8800000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2290000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2666000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2290000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2666000
CY2023Q1 us-gaap Liabilities
Liabilities
12712000
CY2022Q4 us-gaap Liabilities
Liabilities
11466000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38475251
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36694078
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
198144000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194910000
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202880000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197821000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7872000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8451000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2924000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2616000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2227000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2859000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5151000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5475000
CY2023Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-92000
CY2022Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-115000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36735435
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36735435
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36436882
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36436882
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14487000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000
CY2023Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
3230000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-5059000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-5360000
CY2023Q1 us-gaap Depreciation
Depreciation
67000
CY2022Q1 us-gaap Depreciation
Depreciation
74000
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4000
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
505000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-117000
CY2023Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
579000
CY2022Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-323000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1578000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
870000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
82000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
17000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3986000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3688000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2005000
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
8000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2005000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000
CY2023Q1 bcli Proceeds From At Market
ProceedsFromAtMarket
3230000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3230000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1249000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3705000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2021000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15151000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203000000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
CY2023Q1 bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2023Q1 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2023Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
579000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4054000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3679000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3679000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
657000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M9D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1070000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1417000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1315000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
189000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3991000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
312000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3679000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
154000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
217027
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.01
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
35000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.54
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
44005
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.59
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
53827
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
154195
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.66
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y6M10D
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
505000

Files In Submission

Name View Source Status
0001410578-23-001157-index-headers.html Edgar Link pending
0001410578-23-001157-index.html Edgar Link pending
0001410578-23-001157.txt Edgar Link pending
0001410578-23-001157-xbrl.zip Edgar Link pending
bcli-20230331.xsd Edgar Link pending
bcli-20230331x10q.htm Edgar Link pending
bcli-20230331xex31d1.htm Edgar Link pending
bcli-20230331xex31d2.htm Edgar Link pending
bcli-20230331xex32d1.htm Edgar Link pending
bcli-20230331xex32d2.htm Edgar Link pending
bcli-20230331_def.xml Edgar Link unprocessable
bcli-20230331_lab.xml Edgar Link unprocessable
bcli-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20230331x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcli-20230331_cal.xml Edgar Link unprocessable